Advancing crystal polymorph screening with infrared approaches
Monday, July 6 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Identifying and controlling crystal polymorphism remains a critical challenge in pharmaceutical development, with implications for stability, bioavailability, and manufacturability.
In this SelectScience® webinar, NGK Corporation introduces a novel infrared-based screening approach designed to uncover previously undetected crystalline forms and complement existing polymorph screening workflows. Through case studies, attendees will explore how this technique can strengthen risk assessment and support more robust drug development.
An invited lecture from Professor Etsuo Yonemochi, School of Pharmacy at Narita, International University of Health and Welfare, will provide deeper insight into crystal morphology, examining how crystallization conditions influence crystal habit and how these characteristics impact dissolution, wettability, and downstream processing.
Speakers
Featured products
Request Quote for All Products
IR‑Based Polymorph Screening Service
NGK CorporationNGK Corporation offers the world’s first IR‑based polymorph screening service utilizing its proprietary infrared radiation technology. By selectively exciting specific molecular vibrations, this approach provides a novel screening pathway beyond conventional methods. This service enhances the likelihood of discovering previously unknown crystalline forms, aiming to contribute to our clients’ pharmaceutical development.
What will this webinar cover?
- How infrared-based screening can expand polymorph discovery beyond conventional approaches
- Case studies demonstrating how complementary screening strategies improve development robustness
- Insight into crystal morphology and how crystallization conditions influence key pharmaceutical properties
- How computational and structural data can support prediction of formulation-relevant behavior